These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12504677)

  • 1. Protein tyrosine kinases: autoregulation and small-molecule inhibition.
    Hubbard SR
    Curr Opin Struct Biol; 2002 Dec; 12(6):735-41. PubMed ID: 12504677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
    Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
    Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
    Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
    ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
    Lin YL; Roux B
    J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
    Sattler M; Scheijen B; Weisberg E; Griffin JD
    Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity.
    Lorenz S; Deng P; Hantschel O; Superti-Furga G; Kuriyan J
    Biochem J; 2015 Jun; 468(2):283-91. PubMed ID: 25779001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A myristoyl/phosphotyrosine switch regulates c-Abl.
    Hantschel O; Nagar B; Guettler S; Kretzschmar J; Dorey K; Kuriyan J; Superti-Furga G
    Cell; 2003 Mar; 112(6):845-57. PubMed ID: 12654250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
    Schindler T; Bornmann W; Pellicena P; Miller WT; Clarkson B; Kuriyan J
    Science; 2000 Sep; 289(5486):1938-42. PubMed ID: 10988075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
    Frasca F; Vigneri P; Vella V; Vigneri R; Wang JY
    Oncogene; 2001 Jun; 20(29):3845-56. PubMed ID: 11439348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni.
    Beckmann S; Hahnel S; Cailliau K; Vanderstraete M; Browaeys E; Dissous C; Grevelding CG
    J Biol Chem; 2011 Dec; 286(49):42325-42336. PubMed ID: 22013071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
    Lin YL; Meng Y; Jiang W; Roux B
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein tyrosine kinase structure and function.
    Hubbard SR; Till JH
    Annu Rev Biochem; 2000; 69():373-98. PubMed ID: 10966463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
    Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
    Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
    Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of imatinib (STI571).
    Buchdunger E; O'Reilly T; Wood J
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STI-571: an anticancer protein-tyrosine kinase inhibitor.
    Roskoski R
    Biochem Biophys Res Commun; 2003 Oct; 309(4):709-17. PubMed ID: 13679030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.